You have a new or improved treatment for rare pediatric cancers?
let us fund the clinical development of your new therapy
You have a new or improved treatment for rare pediatric cancers?
How we help
The problem
Rare pediatric cancers are not a commercially attractive market. As a consequence, potentially effective therapies are not tested in kids and the standards of care do not improve. We step in to fund and run early-phase trials, lowering the financial risk for developers and enabling promising therapies to reach children sooner.
The solution
Pediatric oncology, GMP, and GCP experts develop the most effective clinical development pathway.
We then fund and execute early phase clinical trials to test the safety and efficacy of the new therapy.